All In Biotech

Drug Trial Radar · NCT04644575

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

261

Actual

Start

Feb 23, 2021

Primary completion

Jan 15, 2027

Study completion Jan 15, 2027

Sponsor

Lead sponsor
Bioverativ, a Sanofi companySanofi (SNY)
Sponsor type
Industry
First posted
Nov 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: \- To evaluate the long-term safety of BIVV001 in previously treated subjects with hemophilia A Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes. * To evaluate BIVV001 consumption for prevention and treatment of bleeding episodes. * To evaluate the effect of BIVV001 prophylaxis on joint health outcomes. * To evaluate the effect of BIVV001 prophylaxis on Quality of Life (QoL) outcomes. * To evaluate the safety and tolerability of BIVV001 treatment. * To assess the PK of BIVV001 based on the one stage activated partial thromboplastin time (aPTT) and two-stage chromogenic FVIII activity assays (only applicable to Arm B). * To evaluate the efficacy of BIVV001 for perioperative management

Conditions

  • Hemophilia A

Interventions

  • efanesoctocog alfa (BIVV001)Drug

    Pharmaceutical form:Solution for Injection Route of administration: Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with the occurrence of inhibitor development (neutralizing antibodies detected against factor VIII [FVIII])Time frame: Baseline to month 48

Locations

85 sites in 23 countries. Site status is shown where the registry gives one.

  • Orthopaedic Institute for Children Site Number : 8400003

    Los Angeles, California

  • Children's Hospital Los Angeles Site Number : 8400009

    Los Angeles, California

  • University of California San Diego Site Number : 8400007

    San Diego, California

  • University of Florida Health Site Number : 8400008

    Gainesville, Florida

  • Children's Healthcare of Atlanta Site Number : 8400016

    Atlanta, Georgia

  • Rush University Medical Center Site Number : 8400010

    Chicago, Illinois

  • Children's Hospital Of Iowa Site Number : 8400011

    Iowa City, Iowa

  • University of Michigan Medical Center Site Number : 8400006

    Ann Arbor, Michigan

  • Michigan State University School Of Med Site Number : 8400002

    East Lansing, Michigan

  • Hemostasis and Thrombosis Center of Nevada Site Number : 8400001

    Las Vegas, Nevada

  • New York Presbyterian Hospital/Weill Cornell Medical Center Site Number : 8400017

    New York, New York

  • East Carolina University -2390 Hemby Ln Site Number : 8400015

    Greenville, North Carolina

  • Cincinnati Children's Hospital Medical Center Site Number : 8400012

    Cincinnati, Ohio

  • Children's Research Institute Site Number : 8400013

    Columbus, Ohio

  • Bloodworks Northwest Site Number : 8400005

    Seattle, Washington

  • Children's Hospital of Wisconsin Site Number : 8400014

    Milwaukee, Wisconsin

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    CABA, Buenos Aires F.D., Argentina

  • Investigational Site Number : 0320002

    Godoy Cruz, Mendoza Province, Argentina

  • Investigational Site Number : 0360004

    Camperdown, New South Wales, Australia

  • Investigational Site Number : 0360001

    Westmead, New South Wales, Australia

  • Investigational Site Number : 0360002

    South Brisbane, Queensland, Australia

  • Investigational Site Number : 0360003

    Murdoch, Western Australia, Australia

  • Investigational Site Number : 0560003

    Woluwe-Saint-Lambert, Belgium

  • Hemocentro Campinas - UNICAMP Site Number : 0760001

    Campinas, São Paulo, Brazil

  • Investigational Site Number : 1000171

    Plovdiv, Bulgaria

  • Investigational Site Number : 1000172

    Sofia, Bulgaria

  • Investigational Site Number : 1240005

    Hamilton, Ontario, Canada

  • Investigational Site Number : 1240004

    Hamilton, Ontario, Canada

  • Investigational Site Number : 1240002

    Ottawa, Ontario, Canada

  • Investigational Site Number : 1240001

    Toronto, Ontario, Canada

  • Investigational Site Number : 1560002

    Beijing, China

  • Investigational Site Number : 1560006

    Beijing, China

  • Investigational Site Number : 1560001

    Guangzhou, China

  • Investigational Site Number : 1560003

    Hangzhou, China

  • Investigational Site Number : 1560004

    Hangzhou, China

  • Investigational Site Number : 1560005

    Jinan, China

  • Investigational Site Number : 1560009

    Kunming, China

  • Investigational Site Number : 1560010

    Kunming, China

  • Investigational Site Number : 1560013

    Lanzhou, China

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.